XT
UNCY icon

XTX Topco’s Unicycive Therapeutics UNCY Stock Holding History

XTX Topco’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.7K Sell
10,600
-12,004
-53% -$88.5K ﹤0.01% 3722
2026
Q1 		$149K Sell
22,604
-12,801
-36% -$83.9K ﹤0.01% 2957
2025
Q4 		$204K Sell
35,405
-2,418
-6% -$12.9K 0.01% 2387
2025
Q3 		$165K Buy
+37,823
New +$165K 0.01% 1909
2025
Q2 		– Sell
-12,323
Closed -$70.8K – 3204
2025
Q1 		$70.8K Sell
12,323
-4,823
-28% -$29.4K ﹤0.01% 1934
2024
Q4 		$136K Buy
17,146
+10,068
+142% +$55.7K 0.01% 1695
2024
Q3 		$28.9K Buy
+7,078
New +$28.4K ﹤0.01% 1785
2023
Q3 		– Sell
-1,446
Closed -$18.5K – 2034
2023
Q2 		$18.5K Buy
+1,446
New +$22.6K ﹤0.01% 1323

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

XTX Topco's UNCY Position: Q2 2026 in Review

XTX Topco reduced its Unicycive Therapeutics (UNCY) stake by 53% in Q2 2026, selling an estimated $88.5K and leaving 10,600 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3722.

XTX Topco first reported a position in UNCY in Q2 2023 and has held it in 8 quarters since. The position peaked at $204K in Q4 2025. 73 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • XTX Topco held 10,600 shares of Unicycive Therapeutics worth $49.7K as of Q2 2026.
  • XTX Topco sold 12,004 Unicycive Therapeutics shares in Q2 2026, an estimated $88.5K.
  • Unicycive Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3722 holding.
  • XTX Topco first reported a position in Unicycive Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • XTX Topco's Unicycive Therapeutics position peaked at $204K in Q4 2025.
  • 73 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.